These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 12679704)

  • 1. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
    Palepu A; Tyndall M; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):522-6. PubMed ID: 12679704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.
    Palepu A; Tyndall MW; Li K; Yip B; O'Shaughnessy MV; Schechter MT; Montaner JS; Hogg RS
    J Urban Health; 2003 Dec; 80(4):667-75. PubMed ID: 14709714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study.
    Hayashi K; Wood E; Kerr T; Dong H; Nguyen P; Puskas CM; Guillemi S; Montaner JS; Milloy MJ
    BMC Infect Dis; 2016 Aug; 16(1):455. PubMed ID: 27568002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.
    Krüsi A; Milloy MJ; Kerr T; Zhang R; Guillemi S; Hogg R; Montaner J; Wood E
    Antivir Ther; 2010; 15(5):789-96. PubMed ID: 20710061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.
    Anema A; Kerr T; Milloy MJ; Feng C; Montaner JS; Wood E
    AIDS Care; 2014 Apr; 26(4):459-65. PubMed ID: 24015838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
    Nolan S; Milloy MJ; Zhang R; Kerr T; Hogg RS; Montaner JS; Wood E
    AIDS Care; 2011 Aug; 23(8):980-7. PubMed ID: 21480010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.
    Kuyper LM; Wood E; Montaner JS; Yip B; O'connell JM; Hogg RS
    J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1470-6. PubMed ID: 15602125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis.
    Azar P; Wood E; Nguyen P; Luma M; Montaner J; Kerr T; Milloy MJ
    BMC Infect Dis; 2015 Apr; 15():193. PubMed ID: 25927573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of illicit drug use and substance abuse treatment on adherence to HAART.
    Hicks PL; Mulvey KP; Chander G; Fleishman JA; Josephs JS; Korthuis PT; Hellinger J; Gaist P; Gebo KA;
    AIDS Care; 2007 Oct; 19(9):1134-40. PubMed ID: 18058397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.
    O'Connell JM; Braitstein P; Hogg RS; Yip B; Craib KJ; O'Shaughnessy MV; Montaner JS; Burdge DR
    Antivir Ther; 2003 Dec; 8(6):569-76. PubMed ID: 14760890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.
    Mocroft A; Madge S; Johnson AM; Lazzarin A; Clumeck N; Goebel FD; Viard JP; Gatell J; Blaxhult A; Lundgren JD
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):369-78. PubMed ID: 10634199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with antiretroviral medication adherence among HIV-positive adults accessing highly active antiretroviral therapy (HAART) in British Columbia, Canada.
    O'Neil CR; Palmer AK; Coulter S; O'Brien N; Shen A; Zhang W; Montaner JS; Hogg RS
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):134-41. PubMed ID: 22318879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.